200 related articles for article (PubMed ID: 33193694)
21. Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β
Cosenza LC; Gasparello J; Romanini N; Zurlo M; Zuccato C; Gambari R; Finotti A
Mol Ther Methods Clin Dev; 2021 Jun; 21():507-523. PubMed ID: 33997100
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
[TBL] [Abstract][Full Text] [Related]
23. Development of gene editing strategies for human β-globin (HBB) gene mutations.
Kalkan BM; Kala EY; Yuce M; Karadag Alpaslan M; Kocabas F
Gene; 2020 Apr; 734():144398. PubMed ID: 31987908
[TBL] [Abstract][Full Text] [Related]
24. Does size matter? Two new deletions in the HBB gene cause β
Ropero P; González Fernández FA; Nieto JM; Recasens V; Montañés Á; Murúzabal MJ; Sarasa M; Fernández C; Villegas A; Benavente CC
Ann Hematol; 2022 Jul; 101(7):1465-1471. PubMed ID: 35467101
[TBL] [Abstract][Full Text] [Related]
25. Association between Different Polymorphic Markers and β-Thalassemia Intermedia in Central Iran.
Sajadpour Z; Amini-Farsani Z; Motovali-Bashi M; Yadollahi M; Khosravi-Farsani N
Hemoglobin; 2020 Jan; 44(1):27-30. PubMed ID: 31899996
[TBL] [Abstract][Full Text] [Related]
26. IVS-II-16 (G>C) (
Uçucu S; Karabıyık T; Azik FM
Hemoglobin; 2021 Jul; 45(4):225-227. PubMed ID: 34396882
[TBL] [Abstract][Full Text] [Related]
27. Induction of therapeutic levels of HbF in genome-edited primary β
Mingoia M; Caria CA; Ye L; Asunis I; Marongiu MF; Manunza L; Sollaino MC; Wang J; Cabriolu A; Kurita R; Nakamura Y; Cucca F; Kan YW; Marini MG; Moi P
Br J Haematol; 2021 Jan; 192(2):395-404. PubMed ID: 33216968
[TBL] [Abstract][Full Text] [Related]
28. CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation.
Gabr H; El Ghamrawy MK; Almaeen AH; Abdelhafiz AS; Hassan AOS; El Sissy MH
Stem Cell Res Ther; 2020 Sep; 11(1):390. PubMed ID: 32912325
[TBL] [Abstract][Full Text] [Related]
29. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.
Pavani G; Fabiano A; Laurent M; Amor F; Cantelli E; Chalumeau A; Maule G; Tachtsidi A; Concordet JP; Cereseto A; Mavilio F; Ferrari G; Miccio A; Amendola M
Blood Adv; 2021 Mar; 5(5):1137-1153. PubMed ID: 33635334
[TBL] [Abstract][Full Text] [Related]
30. Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β
Cosenza LC; Zuccato C; Zurlo M; Gambari R; Finotti A
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292612
[TBL] [Abstract][Full Text] [Related]
31. Molecular Characterization of β-Thalassemia Mutations in Central Vietnam.
Doro MG; Casu G; Frogheri L; Persico I; Triet LPM; Hoa PTT; Hoang NH; Pirastru M; Mereu P; Cucca F; Masala B
Hemoglobin; 2017 Mar; 41(2):96-99. PubMed ID: 28671035
[TBL] [Abstract][Full Text] [Related]
32. Two novel mutations in the 3' untranslated region of the beta-globin gene that are associated with the mild phenotype of beta thalassemia.
Bilgen T; Clark OA; Ozturk Z; Akif Yesilipek M; Keser I
Int J Lab Hematol; 2013 Feb; 35(1):26-30. PubMed ID: 22862814
[TBL] [Abstract][Full Text] [Related]
33. Relative and Absolute Quantification of Aberrant and Normal Splice Variants in
Patsali P; Papasavva P; Christou S; Sitarou M; Antoniou MN; Lederer CW; Kleanthous M
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933098
[TBL] [Abstract][Full Text] [Related]
34. Molecular and phenotype characterization of an elongated β-globin variant produced by HBB:C.313delA.
Lin W; Zhang Q; Shen Z; Qu X; Wang Q; Wei L; Qiu Y; Yang J; Xu X; Lao J
Int J Lab Hematol; 2021 Dec; 43(6):1620-1627. PubMed ID: 34271589
[TBL] [Abstract][Full Text] [Related]
35. Hb Knossos (HBB: c.82G > T), β-globin CD 5 (-CT) (HBB: c.17_18delCT) and δ-globin CD 59 (-a) (HBD: c.179delA) mutations in a Syrian patient with β-thalassemia intermedia.
Moassas F; Nweder MS; Murad H
BMC Pediatr; 2019 Feb; 19(1):61. PubMed ID: 30777047
[TBL] [Abstract][Full Text] [Related]
36. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.
Dever DP; Bak RO; Reinisch A; Camarena J; Washington G; Nicolas CE; Pavel-Dinu M; Saxena N; Wilkens AB; Mantri S; Uchida N; Hendel A; Narla A; Majeti R; Weinberg KI; Porteus MH
Nature; 2016 Nov; 539(7629):384-389. PubMed ID: 27820943
[TBL] [Abstract][Full Text] [Related]
37. Molecular analysis of β-thalassemia patients: first identification of mutations HBB:c.93-2A>G and HBB:c.114G>A in Brazil.
Fernandes AC; Shimmoto MM; Furuzawa GK; Vicari P; Figueiredo MS
Hemoglobin; 2011; 35(4):358-66. PubMed ID: 21797703
[TBL] [Abstract][Full Text] [Related]
38. The effect of HBB: c.*+96T>C (3'UTR +1570 T>C) on the mild b-thalassemia intermedia phenotype.
Bilgen T; Canatan D; Arıkan Y; Yeşilipek A; Keser İ
Turk J Haematol; 2011 Sep; 28(3):219-22. PubMed ID: 27264370
[TBL] [Abstract][Full Text] [Related]
39. The Spectrum of
Bazazzadegan N; Abedini SS; Azarkeivan A; Banihashemi S; Nikzat N; Najmabadi H; Neishabury M
Hemoglobin; 2023 Nov; 47(4):147-151. PubMed ID: 37548174
[TBL] [Abstract][Full Text] [Related]
40. The Prevalence of
Saha J; Panja A; Nayek K
Hemoglobin; 2021 May; 45(3):157-162. PubMed ID: 34060430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
